Genomtec S.A. (FRA:4VI)

Market Cap	13.16M -36.1%
Revenue (ttm)	6.98K +400.0%
Net Income	-2.14M
EPS	-0.14
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.7850
Previous Close	0.7800
Day's Range	0.7700 - 0.7850
52-Week Range	0.7120 - 1.6760
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 30, 2026

About Genomtec

Genomtec S.A. researches and develops a mobile point of care genetic testing platform for the clinical diagnostics market in Poland. The company’s flagship project is the Genomtec ID, a diagnostic platform that enables the detection of pathogens, such as viruses, bacteria, and fungi, as well as genetic mutations through the analysis of biological material of patients using swabs, urine, and saliva. It also develops SNAAT chemistry for mutation detection in oncology. In addition, the company develops and commercializes tests used in the detectio...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2016
• Country: Poland
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 4VI

Financial Performance

In 2025, Genomtec's revenue was 19,000, an increase of 1800.00% compared to the previous year's 1,000. Losses were -10.22 million, -8.80% less than in 2024.

Financial numbers in PLN

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 27, 2026

Data Sources Report a data error